daniquidone
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 24, 2007 (NCT00450502)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ccc2c(c1)CN1C(=O)c3ccccc3C1=N2- Mol. weight
- 249.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL114283 ↗
Also known as
- 8-aminoisoindolo(1,2-b)quinazolin-12(10h)one
- batracylin
- batracylin
- batracylin
- batracylin
- bay h 2049
- bay h-2049
- daniquidone
- daniquidone
- nsc 320846
- nsc-320846
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00450502 | Phase 1 | Feb 24, 2007 | National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1